A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
OUTLINE: This is a randomized, placebo-controlled, double-blind, multicenter, 2 arm study.
The study population will consist of prostate cancer patients with metastatic bone disease
for whom androgen-deprivation therapy is planned. After stratification based on the
patient's age, performance status, and severity of metastatic disease, the patients will be
randomized at a 1:1 ratio to the following treatment arms:
- Daily oral risedronate combined with androgen deprivation
- Daily oral placebo combined with androgen deprivation
Initial clinical evaluation will be performed during the 2-week screening period. While
patients receive per-protocol treatment, study assessments will be performed every 4 weeks
during the first 3 months, and every 12 weeks thereafter.
Performance Status: ECOG 0 to 2
Life Expectancy: At least 12 weeks
Hematopoietic:
- ANC > 1,000/mm3
- Platelet count > 100,000/mm3
- INR < 1.5 x upper limit of normal unless on therapeutic anticoagulation
- Partial thromboplastin time (PTT) < 1.5 x upper limit of normal unless on therapeutic
anticoagulation
Hepatic:
- Bilirubin < 1.5 mg/dL
- Alanine transaminase (ALT) < 2.5 x upper limit of normal
Renal:
- Creatinine clearance of > 30 mL/min (by Cockcroft-Gault)
Cardiovascular:
- No significant history of uncontrolled cardiac disease (i.e., uncontrolled
hypertension, unstable angina, and congestive heart failure).
Pulmonary:
- Not specified
Calcium:
- Corrected serum calcium = (4.0 g/dL - actual albumin g/dL)x 0.8 + serum calcium
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
To evaluate the ability of risedronate to prevent skeletal complications
36 months
No
Christopher Sweeney, M.B.B.S.
Study Chair
Hoosier Oncology Group, LLC
United States: Food and Drug Administration
HOG GU02-41
NCT00216060
October 2003
March 2008
Name | Location |
---|---|
Cleveland Clinic Foundation | Cleveland, Ohio 44195 |
Indiana University Cancer Center | Indianapolis, Indiana 46202-5265 |
Cancer Institute of New Jersey | New Brunswick, New Jersey 08901 |
Gundersen Lutheran Medical Center | La Crosse, Wisconsin 54601 |
Peoria Urological Associates | Peoria, Illinois 61614 |
San Bernadino Urological Associates | San Bernadino, California 92404 |
Siteman Cancer Center | Saint Louis, Missouri 63110 |
Center for Cancer Care at Goshen Health System | Goshen, Indiana 46526 |
Urology of Indiana, LLC | Indianapolis, Indiana 46202 |
Center for Urological Research | La Mesa, California 91942 |
Drs. Werner, Murdock and Francis PA Urology Associates | Greenbelt, Maryland 20770 |
Kansas City Urology Care | Kansas City, Missouri 64131 |
AccuMed Research Associates | Garden City, New York 11530 |
Oregon Urology Specialists | Eugene, Oregon 97401 |
Urological Associates Of Lancaster | Lancaster, Pennsylvania 17604-3200 |
Salt Lake Research | Salt Lake City, Utah 84124 |
Lawrenceville Urology | Lawrenceville, New Jersey 08648 |
Northern Indiana Cancer Research Consortium | South Bend, Indiana |
Triangle Urological Group | Pittsburgh, Pennsylvania 15212 |
Mayo Clinic Rochester | Rochester, Minnesota 55905 |
Medical & Surgical Specialists, LLC | Galesburg, Illinois 61401 |
Oncology Hematology Associates of SW Indiana | Evansville, Indiana 47714 |
Quality Cancer Center (MCGOP) | Indianapolis, Indiana 46202 |
Grove Hill Medical Center Urology | New Britain, Connecticut 06052 |
Innovative Surgical Resources | Tampa, Florida 33607 |
Urology Associates | Muncie, Indiana 47303 |
Urologic Surgery Associates | Baltimore, Maryland 21201 |
Nevada Urology | Reno, Nevada 89511 |
Staten Island Urological Research, P.C. | Staten Island, New York 10304 |
David Reed, M.D. | Seattle, Washington 98166 |
Madigan Army Medical Center Urology Service | Tacoma, Washington 98431 |